読み込み中
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
前日終値
$11.70
+$0.58 · +5.22%
時間外
$11.52
−$0.18 · -1.54%
10月9日 19:33 ET
日中の時刻はETです。市場データは遅延する場合があります。
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
日中レンジ
現在 $11.70
52週レンジ
現在 $11.70
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
68
強気
リスク
53
やや高いリスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
日中レンジ
現在 $11.70
52週レンジ
現在 $11.70
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6855.6万 USD | 7420.5万 USD | 8618万 USD | 16.16億 USD | 10.95億 USD |
| 売上原価 | 1170.6万 USD | 1540.4万 USD | 2221.6万 USD | 1.62億 USD | 7167.6万 USD |
| 粗利益 | 5685万 USD | 5880.1万 USD | 6396.4万 USD | 14.54億 USD | 10.24億 USD |
| 研究開発 | 4.33億 USD | 4.63億 USD | 5.51億 USD | 4.68億 USD | 4.42億 USD |
| 販売・一般管理 | 9207.4万 USD | 1.19億 USD | 1.74億 USD | 1.53億 USD | 1.61億 USD |
| 営業費用 | 5.25億 USD | 5.82億 USD | 7.25億 USD | 6.21億 USD | 6.03億 USD |
| 受取利息 | 4023.8万 USD | 7180.9万 USD | 8699万 USD | 2809.2万 USD | 43.9万 USD |
| 減価償却費と償却費 | 1168万 USD | 1455.9万 USD | 1945.1万 USD | 1549.2万 USD | 1198.3万 USD |
| 営業利益 | −4.68億 USD | −5.23億 USD | −6.61億 USD | 8.33億 USD | 4.21億 USD |
| 純利益 | −4.38億 USD | −5.22億 USD | −6.15億 USD | 5.16億 USD | 5.29億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$23.50
上昇余地（100.85%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI5302.2万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3994.57万0.05%782.66億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB3819.45万0.02%1853億 USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI2937.5万0.29%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK2187.58万0.05%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1547.77万0.02%954億 USD0.05%$235+0.80%
iShares Russell 2000 Value ETFIWN1409.89万0.10%138.48億 USD0.24%$210.87-0.04%
Dimensional - US Small Cap ETFDFAS1322.98万0.04%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
